What diagnostic testing and treatment recommendations should be followed for an adolescent with suspected histoplasmosis?

Histoplasmosis in Adolescents: Diagnostic Testing and Treatment

For adolescents with suspected histoplasmosis, obtain tissue biopsy with fungal stains and culture, plus Histoplasma antigen testing in urine and serum for rapid diagnosis, and treat based on disease severity: mild cases often require no treatment, while moderate-to-severe disease requires amphotericin B followed by itraconazole. 1, 2

Diagnostic Testing Approach

Tissue Diagnosis (Highest Priority)

• Obtain tissue biopsy whenever possible for histopathological diagnosis using Grocott methenamine silver (GMS) or periodic acid-Schiff (PAS) staining 1
• Tissue examination sensitivity varies with disease burden and immune status
• Submit all biopsied tissue for fungal culture—most labs identify isolates using DNA probe 1

Antigen Testing

• Histoplasma antigen detection in urine and serum provides rapid diagnosis of probable histoplasmosis 1
• Particularly useful in disseminated disease and for longitudinal monitoring
• Testing multiple body fluids increases diagnostic yield 3
• Note: Antigen tests are usually negative in chronic pulmonary histoplasmosis 2

Blood Cultures

• Conventional blood cultures have ~50% sensitivity in immunocompromised patients 1
• Lysis-centrifugation method improves sensitivity when available 1
• Use aerobic bottles for blood cultures 1

Serological Testing

• Most useful for chronic pulmonary histoplasmosis 1
• Limited utility in severely immunosuppressed patients 1
• Not recommended for monitoring treatment response due to insufficient data 2

Imaging

• Obtain chest, abdominal, and CNS imaging based on clinical presentation 1

---

Treatment Recommendations by Disease Severity

Mild-to-Moderate Acute Pulmonary Histoplasmosis

Treatment is usually unnecessary in adolescents with mild symptoms 2

• Evidence from school outbreaks shows 95% of cases resolve within 3 weeks without treatment 2
• If symptoms persist >1 month: Itraconazole 200 mg three times daily for 3 days, then 200 mg once or twice daily for 6-12 weeks 2

Moderately Severe to Severe Acute Pulmonary Histoplasmosis

Initial therapy:

• Lipid formulation of amphotericin B (3.0-5.0 mg/kg IV daily) for 1-2 weeks 2
• Alternative: Amphotericin B deoxycholate (0.7-1.0 mg/kg IV daily) in patients at low risk for nephrotoxicity 2

Step-down therapy:

• Itraconazole 200 mg three times daily for 3 days, then 200 mg twice daily for total of 12 weeks 2

Adjunctive corticosteroids:

• Methylprednisolone (0.5-1.0 mg/kg IV daily) during first 1-2 weeks if hypoxemia or significant respiratory distress develops 2

Progressive Disseminated Histoplasmosis

For moderately severe to severe disease:

• Liposomal amphotericin B 3.0 mg/kg IV daily for 1-2 weeks 2, 4
• Alternative lipid formulations at 5.0 mg/kg daily acceptable 2
• Amphotericin B deoxycholate (0.7-1.0 mg/kg daily) alternative in low nephrotoxicity risk 2

Maintenance therapy:

• Itraconazole 200 mg orally three times daily for 3 days, then 200 mg twice daily for at least 12 months 2

Special considerations for adolescents:

• Itraconazole dosing in children/adolescents: 5.0-10.0 mg/kg daily (up to adult dose) 2
• Lifelong suppressive therapy may be required if immunosuppression cannot be reversed 2

---

Critical Monitoring Requirements

Itraconazole Therapeutic Drug Monitoring

• Measure itraconazole blood levels after 2 weeks to ensure adequate drug exposure 2
• Target: Itraconazole concentration >1.0 mcg/mL 5
• Combined itraconazole plus hydroxy-itraconazole >1.0 mcg/mL also acceptable 5
• Subtherapeutic levels associated with 67.9% response rate vs. 90-95% with adequate levels 5

Antigen Monitoring

• Monitor antigen levels during therapy and for 12 months after completion 2
• Useful for detecting relapse
• Persistent low-level antigenuria may not require treatment prolongation if patient clinically well 2

Amphotericin B Monitoring

• Monitor electrolytes, renal function, and blood counts several times per week 2

---

Common Pitfalls and Caveats

Drug Interactions

• Do not give itraconazole with contraindicated medications: pimozide, quinidine, dofetilide, lovastatin, simvastatin, midazolam, triazolam 2

Fluconazole Caution

• Fluconazole has lower success rates than itraconazole 1
• Resistance emergence reported with fluconazole therapy 1
• Not recommended for histoplasmosis treatment

Immunosuppression Management

• Discontinue TNF-α inhibitors during antifungal therapy if histoplasmosis develops 1
• May reinstitute immunosuppression after ~12 months of treatment if antigen tests negative 1

Meningitis in Adolescents

• Unlike adults, CNS involvement in disseminated histoplasmosis of infancy/childhood responds well to amphotericin B deoxycholate (4-6 weeks) without high relapse rates 2
• Treatment for disseminated disease does not need modification for CNS involvement in younger patients 2

When to Avoid Treatment

• Asymptomatic pulmonary nodules (histoplasmomas) do not require treatment 2
• Pericarditis and rheumatologic syndromes typically respond to NSAIDs alone without antifungals 2
• Only add itraconazole if corticosteroids are required 2